■随着生物疗法的引入,Behçet病的治疗得到了显着改善。然而,仍然需要更多关于它们使用的信息。本研究旨在评估适应症,回应,和生物制剂在伊朗南部难治性或严重Behçet病患者中的副作用,他们的后续行动和改变生物制剂的原因。
■对44名年龄在16-65岁之间、服用生物制剂至少6个月的患者进行了回顾性分析。临床病史,在6个月和12个月时部分和完全缓解,副作用的发生,并记录了是否需要转换为第二种或第三种生物制剂。
■起始生物制剂的最常见适应症是眼科(68.2%),脑实质受累(15.9%),关节炎(11.4%)。在Behçet病的各种表现中观察到改善,在86、51.6、92.8、66.7、42.9、33.3和80.0%的口腔口疮病变中完全缓解,眼科活动,生殖器口疮性病变,皮肤活动,关节炎,脑实质病变,血管活动,分别,开始使用生物制剂后6个月。在12个月的随访中,这些比率没有变化或增加。在25.0%的患者中,由于严重的疾病,必须转换为第二种生物制剂,副作用,或难治性疾病。在使用第一和第二生物制剂的患者中,有16.3%和33.3%的患者出现副作用,分别。大多数副作用并不严重。
■在6个月和12个月的随访中,我们发现各种生物制剂在治疗Behçet病方面具有可接受的安全性。
UNASSIGNED: The treatment of Behçet\'s disease has improved significantly with the introduction of biologic therapies. However, there is still a need for more information about their use. This study aimed to evaluate the indications, response, and side effects of biologic agents in patients with refractory or severe Behçet\'s disease in the south of Iran, their follow-up and reasons for changing the biologics.
UNASSIGNED: A retrospective analysis was conducted on 44 patients aged 16-65 years who were prescribed biologic agents for at least 6 months. The clinical history, partial and complete remission at 6 and 12 months, occurrence of side effects, and need for switching to a second or third biologic agent were recorded.
UNASSIGNED: The most common indications for starting biologic agents were ophthalmic (68.2%), parenchymal brain involvement (15.9%), and arthritis (11.4%). Improvement was observed in various manifestations of Behçet\'s disease, with complete remission in 86, 51.6, 92.8, 66.7, 42.9, 33.3, and 80.0% of oral aphthous lesions, ophthalmic activity, genital aphthous lesions, skin activity, arthritis, brain parenchymal lesions, and vascular activity, respectively, 6 months after starting biologic agents. These rates were unchanged or increased at the 12-month follow-up. In 25.0% of patients, a switch to a second biologic agent was necessary due to severe disease, side effects, or refractory disease. Side effects occurred in 16.3% and 33.3% of patients on the first and second biologic agents, respectively. The majority of side effects were not serious.
UNASSIGNED: We found a promising improvement at 6-month and 12-month follow-ups with various biologic agents in treating Behçet\'s disease with an acceptable safety profile.